Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0L9XF
|
|||
| Former ID |
DNCL002286
|
|||
| Drug Name |
BBI503
|
|||
| Indication | Cholangiocarcinoma [ICD-11: 2C12.10; ICD-10: C22.1] | Phase 2 | [1] | |
| Hepatocellular carcinoma [ICD-11: 2C12.02; ICD-10: C22.0] | Phase 2 | [1] | ||
| Ovarian cancer [ICD-11: 2C73; ICD-10: C56] | Phase 2 | [1] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 2 | [2] | ||
| Company |
Boston Biomedical
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C31H33N5O2S
|
|||
| Canonical SMILES |
CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)C4=CSC(=N4)C5=CC=CC=C5)NC2=O)C
|
|||
| InChI |
1S/C31H33N5O2S/c1-5-36(6-2)15-14-32-30(38)28-19(3)26(33-20(28)4)17-24-23-16-22(12-13-25(23)34-29(24)37)27-18-39-31(35-27)21-10-8-7-9-11-21/h7-13,16-18,33H,5-6,14-15H2,1-4H3,(H,32,38)(H,34,37)/b24-17-
|
|||
| InChIKey |
QDWKGEFGLQMDAM-ULJHMMPZSA-N
|
|||
| CAS Number |
CAS 1129403-56-0
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cancer stemness kinase (CSK) | Target Info | Inhibitor | [2] |
| Serine/threonine-protein kinase (STK) | Target Info | Inhibitor | [2] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02232633) A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.